CN102946883A - 治疗视网膜疾病的方法及眼用组合物 - Google Patents

治疗视网膜疾病的方法及眼用组合物 Download PDF

Info

Publication number
CN102946883A
CN102946883A CN2011800290140A CN201180029014A CN102946883A CN 102946883 A CN102946883 A CN 102946883A CN 2011800290140 A CN2011800290140 A CN 2011800290140A CN 201180029014 A CN201180029014 A CN 201180029014A CN 102946883 A CN102946883 A CN 102946883A
Authority
CN
China
Prior art keywords
patient
ophthalmic composition
fatty acid
eyes
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800290140A
Other languages
English (en)
Chinese (zh)
Inventor
真岛行彦
上野隆司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of CN102946883A publication Critical patent/CN102946883A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
CN2011800290140A 2010-04-12 2011-04-12 治疗视网膜疾病的方法及眼用组合物 Pending CN102946883A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US32333810P 2010-04-12 2010-04-12
US32334210P 2010-04-12 2010-04-12
US61/323338 2010-04-12
US61/323342 2010-04-12
US32681110P 2010-04-22 2010-04-22
US61/326811 2010-04-22
US36294510P 2010-07-09 2010-07-09
US61/362945 2010-07-09
US40823710P 2010-10-29 2010-10-29
US61/408237 2010-10-29
PCT/JP2011/059479 WO2011129461A1 (en) 2010-04-12 2011-04-12 Method and ophthalmic composition for treating retinal disease

Publications (1)

Publication Number Publication Date
CN102946883A true CN102946883A (zh) 2013-02-27

Family

ID=44798822

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800290140A Pending CN102946883A (zh) 2010-04-12 2011-04-12 治疗视网膜疾病的方法及眼用组合物
CN201180028968XA Pending CN102933217A (zh) 2010-04-12 2011-04-12 用于治疗黄斑水肿的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180028968XA Pending CN102933217A (zh) 2010-04-12 2011-04-12 用于治疗黄斑水肿的药物组合物

Country Status (9)

Country Link
US (2) US20110275715A1 (https=)
EP (2) EP2558104A4 (https=)
JP (3) JP5686819B2 (https=)
KR (2) KR20130050939A (https=)
CN (2) CN102946883A (https=)
AR (1) AR080888A1 (https=)
CA (2) CA2795723A1 (https=)
TW (2) TW201204366A (https=)
WO (2) WO2011129461A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010323566B2 (en) * 2009-11-27 2014-06-05 R-Tech Ueno, Ltd. Method for screening drug efficacious in treating dry eye and/or keratoconjunctival disorders and pharmaceutical composition obtained thereby
KR20140038404A (ko) * 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
WO2013126799A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
WO2018036498A1 (en) * 2016-08-24 2018-03-01 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
WO2020206098A1 (en) * 2019-04-03 2020-10-08 Regenxbio Inc. Gene therapy for eye pathologies
EP4050997A4 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
EP4329753A4 (en) 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
FI131849B1 (en) * 2024-09-10 2026-01-09 Pixieray Oy METHOD AND OPTICAL DEVICE FOR MONITORING THE USE OF EYE DROPS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005815A1 (en) * 2000-07-13 2002-01-24 Pharmacia & Upjohn Company Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052876A1 (en) * 2000-01-18 2001-07-26 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2003020283A2 (en) * 2001-08-29 2003-03-13 Novartis Ag Method for treating diabetic retinopathy
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
ES2431640T3 (es) * 2003-08-21 2013-11-27 Sucampo Ag Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005815A1 (en) * 2000-07-13 2002-01-24 Pharmacia & Upjohn Company Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIRAMATSU A,ET AL: "Study of effects of unoprostone eye drops on macular area visual function in patients with retinitis pigmenosa and background of them", 《分担研究报告书》 *

Also Published As

Publication number Publication date
EP2558103A4 (en) 2013-09-25
JP5878128B2 (ja) 2016-03-08
CN102933217A (zh) 2013-02-13
WO2011129457A1 (en) 2011-10-20
AR080888A1 (es) 2012-05-16
KR20130099812A (ko) 2013-09-06
JP2013523601A (ja) 2013-06-17
US20110275715A1 (en) 2011-11-10
CA2795723A1 (en) 2011-10-20
CA2795720A1 (en) 2011-10-20
EP2558104A1 (en) 2013-02-20
JP5686819B2 (ja) 2015-03-18
KR20130050939A (ko) 2013-05-16
EP2558103A1 (en) 2013-02-20
JP2016026182A (ja) 2016-02-12
US20110275711A1 (en) 2011-11-10
TW201204366A (en) 2012-02-01
WO2011129461A1 (en) 2011-10-20
TW201141486A (en) 2011-12-01
EP2558104A4 (en) 2013-12-11
JP2013528563A (ja) 2013-07-11

Similar Documents

Publication Publication Date Title
JP5878128B2 (ja) 網膜疾患を処置するための方法および眼科用組成物
EP2262476B1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
US20040213782A1 (en) Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
US9974685B2 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
US20240342174A1 (en) Methods for treating ocular surface pain
US20120087864A1 (en) Method for diagnosing and/or evaluating retinal disease
US9636347B2 (en) Sustained release formulations for the treatment of intraocular pressure or glaucoma
JP2009519962A (ja) 眼投与用局所メカミルアミン製剤およびその使用
US8889735B2 (en) Method for treating asthenopia
CN102762195B (zh) 前列腺素激动剂前药的稳定水性组合物及其使用方法
Denis et al. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution
JP2009506113A (ja) 緑内障治療のためのｅｐ２レセプターアゴニスト
EP2844224A1 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP3108887A1 (en) Pharmaceutical composition for treating geographic atrophy associated with age-related macular degeneration
HK1181675A (en) Pharmaceutical composition for treating macular edema

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130227